martedì 26 maggio 2020

FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression - FDA also approved the VENTANA PD-L1 (SP142) Assay as a companion diagnostic

Fonte: ESMO European Society for Medical Oncology

Link all'articolo completo